{
  "docId": "019dd923-5ca1-7489-b638-229be117d58e",
  "docSlug": "415e33cb189c4261",
  "documentTitle": "Impact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 5,
  "pageCount": 13,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "icon_grid",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-229be117d58e/5",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e#slide-5",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Sixty-eight percent of the life sciences companies are adjusting their actions, including increasing legal and compliance requirements, diversifying partnerships and adding background checks for existing partners.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cc5-df259e9c6410",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dce27ca-6c9b-471c-b217-f4cff0c4121d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.35,
        "y": 0.2
      },
      "kind": "list",
      "text": "Confidence in working with Chinese companies has dropped by 30-50% for US-based life sciences companies, with CDMOs being the worst hit. Those outside of the US are also concerned, though much less so (20-30% decrease in confidence level).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d0094a1-2b13-4564-aacd-9e722c785c15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.35,
        "y": 0.72
      },
      "kind": "list",
      "text": "Amid the US-China biotechnology decoupling threats, the majority of the biopharma still show high interest to partner with Chinese companies for product commercialization. Collaboration with Chinese service providers in clinical research, development and manufacturing are also not completely off the table, with approximately 30% of respondents considering these partnerships as likely in the next three years.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fdfb23e-8606-452b-99dd-06027b241066",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.35,
        "y": 0.55
      },
      "kind": "list",
      "text": "Sixty-eight percent of the life sciences companies are adjusting their actions, including increasing legal and compliance requirements, diversifying partnerships and adding background checks for existing partners. Few companies (13%) based in Asia (ex-China) are actively considering diversifying partnerships to other countries; however, background checks for existing partners are frequently reported (38%).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa86c135-21e0-4776-a3ca-feefcc2a2310",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.35,
        "y": 0.38
      },
      "kind": "list",
      "text": "Twenty-six percent of the life sciences companies are looking to shift away from their current Chinese partners. Only 2%, however, have taken actual steps to unwind relationships with companies named in the US BIOSECURE Act. Still 11% of the life sciences companies report no impact on their partnership decisions.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff245b8c-1336-4769-9911-26c18f09a4d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Confidence level: 68%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cc5-e2a758e0af9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Key findings of L.E.K.'s 2024 Global Survey on Impact of the US BIOSECURE Act suggests that industry has started to take precautionary measures, but many remain keen to work with Chinese companies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5302ebb-e6cc-42ab-a544-7df86421b1f2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Confidence level",
      "numberRaw": "68%",
      "numberKind": "percent",
      "actionTitle": "Key findings of L.E.K.'s 2024 Global Survey on Impact of the US BIOSECURE Act suggests that industry has started to take precautionary measures, but many remain keen to work with Chinese companies",
      "calloutText": "Sixty-eight percent of the life sciences companies are adjusting their actions, including increasing legal and compliance requirements, diversifying partnerships and adding background checks for existing partners.",
      "numberScale": null,
      "numberValue": 68,
      "metricFamily": "index_score",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "62cb5ef7-b2aa-470b-9a14-de03e71a4028",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The document highlights the potential impact of the Act on biopharmas and contract services",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "04a5278d-7e5b-4b55-a8c7-0de1c16bfa6b",
      "evidence": "The document presents data on the potential impact of the Act on partnerships with Chinese companies",
      "position": 0,
      "objective": "Highlighting the consequences of not adapting to the US BIOSECURE Act",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}